Mouse Anti-NCOA2 Recombinant Antibody (CBYJT-1488) (CBMAB-T0519-YJ)

Name: Mouse Anti-NCOA2 Recombinant Antibody (CBYJT-1488)
SKU: CBMAB-T0519-YJ
Rating: 5 (1 reviews)

See all NCOA2 antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

CBYJT-1488

Application

ELISA, WB, IC

Specificity

Human

Antibody Isotype

IgG1, κ

Clonality

Monoclonal

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Buffer

PBS, pH 7.4

Storage

Store at 4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

More Infomation

Target

Full Name

Nuclear Receptor Coactivator 2

Introduction

NCOA2 plays a role as a transcriptional coactivator for nuclear hormone receptors, including steroid, thyroid, retinoid, and vitamin D receptors. NCOA2 acts as an intermediary factor for the ligand-dependent activity of these nuclear receptors, which regulate their target genes upon binding of cognate response elements. It has been found to be involved in translocations that result in fusions with other genes in various cancers, including the lysine acetyltransferase 6A (KAT6A) gene in acute myeloid leukemia, the ETS variant 6 (ETV6) gene in acute lymphoblastic leukemia, and the hes related family bHLH transcription factor with YRPW motif 1 (HEY1) gene in mesenchymal chondrosarcoma.

Entrez Gene ID

10499

UniProt ID

Q15596

Alternative Names

Nuclear Receptor Coactivator 2; Class E Basic Helix-Loop-Helix Protein 75; Transcriptional Intermediary Factor 2; BHLHe75; NCoA-2; SRC2; TIF2

Function

Transcriptional coactivator for steroid receptors and nuclear receptors (PubMed:8670870, PubMed:23508108, PubMed:9430642).

Coactivator of the steroid binding domain (AF-2) but not of the modulating N-terminal domain (AF-1) (PubMed:8670870, PubMed:23508108, PubMed:9430642).

Required with NCOA1 to control energy balance between white and brown adipose tissues (PubMed:8670870, PubMed:23508108, PubMed:9430642).

Critical regulator of glucose metabolism regulation, acts as RORA coactivator to specifically modulate G6PC1 expression (PubMed:8670870, PubMed:23508108, PubMed:9430642).

Involved in the positive regulation of the transcriptional activity of the glucocorticoid receptor NR3C1 by sumoylation enhancer RWDD3 (PubMed:23508108).

Positively regulates the circadian clock by acting as a transcriptional coactivator for the CLOCK-ARNTL/BMAL1 heterodimer (By similarity).

Biological Process

Cellular response to hormone stimulus Source: GO_Central
Cellular response to Thyroglobulin triiodothyronine Source: Ensembl
Circadian regulation of gene expression Source: UniProtKB
Locomotor rhythm Source: Ensembl
mRNA transcription by RNA polymerase II Source: ComplexPortal
Negative regulation of transcription by RNA polymerase II Source: Ensembl
Peroxisome proliferator activated receptor signaling pathway Source: ComplexPortal
Positive regulation of adipose tissue development Source: ComplexPortal
Positive regulation of transcription by RNA polymerase II Source: ComplexPortal
Regulation of cellular response to insulin stimulus Source: ComplexPortal
Regulation of glucose metabolic process Source: Ensembl
Regulation of transcription, DNA-templated Source: UniProtKB
Response to progesterone Source: Ensembl

Involvement in disease

Chromosomal aberrations involving NCOA2 may be a cause of acute myeloid leukemias. Inversion inv(8)(p11;q13) generates the KAT6A-NCOA2 oncogene, which consists of the N-terminal part of KAT6A and the C-terminal part of NCOA2/TIF2. KAT6A-NCOA2 binds to CREBBP and disrupts its function in transcription activation.

PTM

Acetylated. Deacetylation at Lys-780 by SIRT6 stimulates its ability to coactivate PPARA.

Smith, B. F., Doung, Y. C., Beckett, B., Corless, C. L., Davis, L. E., & Davis, J. L. (2023). Intraosseous spindle cell rhabdomyosarcoma with MEIS1:: NCOA2 fusion–case report with substantial clinical follow-up and review of the literature. Cancer Investigation, 41(8), 704-712.

Qi, W., Rosikiewicz, W., Yin, Z., Xu, B., Jiang, H., Wan, S., ... & Wang, L. (2022). Genomic profiling identifies genes and pathways dysregulated by HEY1–NCOA2 fusion and shines a light on mesenchymal chondrosarcoma tumorigenesis. The Journal of Pathology, 257(5), 579-592.

Yin, X., Wang, M., He, H., Ru, G., & Zhao, M. (2022). Uterine tumor resembling ovarian sex cord tumor with aggressive histologic features harboring a GREB1-NCOA2 fusion: case report with a brief review. International Journal of Gynecological Pathology.

Fishman, H., Madiwale, S., Geron, I., Bari, V., Van Loocke, W., Kirschenbaum, Y., ... & Izraeli, S. (2022). ETV6-NCOA2 fusion induces T/myeloid mixed-phenotype leukemia through transformation of nonthymic hematopoietic progenitor cells. Blood, The Journal of the American Society of Hematology, 139(3), 399-412.

Li, C., Chen, S., Jia, W., Li, W., Wei, D., Cao, S., ... & Lei, D. (2022). Identify metabolism-related genes IDO1, ALDH2, NCOA2, SLC7A5, SLC3A2, LDHB, and HPRT1 as potential prognostic markers and correlate with immune infiltrates in head and neck squamous cell carcinoma. Frontiers in immunology, 13, 955614.

Kao, Y. C., Bennett, J. A., Suurmeijer, A. J., Dickson, B. C., Swanson, D., Wanjari, P., ... & Antonescu, C. R. (2021). Recurrent MEIS1-NCOA2/1 fusions in a subset of low-grade spindle cell sarcomas frequently involving the genitourinary and gynecologic tracts. Modern Pathology, 34(6), 1203-1212.

Devereaux, K. A., Kertowidjojo, E., Natale, K., Ewalt, M. D., Soslow, R. A., & Hodgson, A. (2021). GTF2A1-NCOA2-associated uterine tumor resembling ovarian sex cord tumor (UTROSCT) shows focal rhabdoid morphology and aggressive behavior. The American Journal of Surgical Pathology, 45(12), 1725-1728.

Lin, Z., Yang, F., Lu, D., Sun, W., Zhu, G., & Lan, B. (2020). Knockdown of NCOA2 Inhibits the Growth and Progression of Gastric Cancer by Affecting the Wnt Signaling Pathway–Related Protein Expression. Technology in Cancer Research & Treatment, 19, 1533033820928072.

Wei, X., Bai, L., Dong, L., Liu, H., Xing, P., Zhou, Z., ... & Lan, K. (2019). NCOA2 promotes lytic reactivation of Kaposi’s sarcoma-associated herpesvirus by enhancing the expression of the master switch protein RTA. PLoS Pathogens, 15(11), e1008160.

Dickson, B. C., Childs, T. J., Colgan, T. J., Sung, Y. S., Swanson, D., Zhang, L., & Antonescu, C. R. (2019). Uterine tumor resembling ovarian sex cord tumor: a distinct entity characterized by recurrent NCOA2/3 gene fusions. The American journal of surgical pathology, 43(2), 178.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-NCOA2 Recombinant Antibody (CBYJT-1488)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Related Products

Mouse Anti-NCOA2 Recombinant Antibody (3C7) (CAT#: CBMAB-N1440-WJ)

Mouse Anti-NCOA2 Recombinant Antibody (7G5) (CAT#: CBMAB-N1441-WJ)

Mouse Anti-NCOA2 Recombinant Antibody (CBWJN-0310) (CAT#: CBMAB-N0181-WJ)

Mouse Anti-NCOA2 Recombinant Antibody (CBYJT-1490) (CAT#: CBMAB-T0521-YJ)

Mouse Anti-NCOA2 Recombinant Antibody (CBWJN-0956) (CAT#: CBMAB-N0182-WJ)

Mouse Anti-NCOA2 Recombinant Antibody (GRP01) (CAT#: CBMAB-K2179-LY)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry